BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)
Public ClinicalTrials.gov record NCT00605215. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multinational, Multicenter, Randomized, Parallel-Group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Laquinimod Over Placebo in a Double-blind Design and of a Reference Arm of Interferon β-1a (Avonex®) in a Rater-blinded Design
Study identification
- NCT ID
- NCT00605215
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Enrollment
- 1,331 participants
Conditions and interventions
Conditions
Interventions
- Laquinimod Drug
- Placebo Drug
- Avonex® Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 23, 2008
- Primary completion
- Jun 9, 2011
- Completion
- Jun 9, 2011
- Last update posted
- Apr 20, 2022
2008 – 2011
United States locations
- U.S. sites
- 36
- U.S. states
- 23
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 1267 | Birmingham | Alabama | 35209 | — |
| Teva Investigational Site 1237 | Phoenix | Arizona | 85013 | — |
| Teva Investigational Site 1252 | Phoenix | Arizona | 85018 | — |
| Teva Investigational Site 1279 | Phoenix | Arizona | 85018 | — |
| Teva Investigational Site 1276 | Tucson | Arizona | 85741-3537 | — |
| Teva Investigational Site 1272 | Pasadena | California | 91105 | — |
| Teva Investigational Site 1238 | Sacramento | California | 95817 | — |
| Teva Investigational Site 1280 | Aurora | Colorado | 80045 | — |
| Teva Investigational Site 1255 | Orlando | Florida | 32806 | — |
| Teva Investigational Site 1282 | Sarasota | Florida | 34233 | — |
| Teva Investigational Site 1275 | Atlanta | Georgia | 30309 | — |
| Teva Investigational Site 1250 | Peoria | Illinois | 61603 | — |
| Teva Investigational Site 1260 | Indianapolis | Indiana | 46202 | — |
| Teva Investigational Site 1268 | Lenexa | Kansas | 66214 | — |
| Teva Investigational Site 1277 | New Orleans | Louisiana | 70115 | — |
| Teva Investigational Site 1263 | Shreveport | Louisiana | 71103 | — |
| Teva Investigational Site 1269 | Baltimore | Maryland | 21201 | — |
| Teva Investigational Site 1274 | Grand Rapids | Michigan | 49525 | — |
| Teva Investigational Site 1239 | Lebanon | New Hampshire | 03766 | — |
| Teva Investigational Site 1265 | Teaneck | New Jersey | 07666 | — |
| Teva Investigational Site 1273 | Albany | New York | 12205 | — |
| Teva Investigational Site 1264 | Amherst | New York | 14226 | — |
| Teva Investigational Site 1283 | Cedarhurst | New York | 11516 | — |
| Teva Investigational Site 1249 | Raleigh | North Carolina | 27607 | — |
| Teva Investigational Site 1262 | Winston-Salem | North Carolina | 27103 | — |
| Teva Investigational Site 1261 | Akron | Ohio | 44320 | — |
| Teva Investigational Site 1241 | Canton | Ohio | 44718 | — |
| Teva Investigational Site 1245 | Cleveland | Ohio | 44195-5244 | — |
| Teva Investigational Site 1247 | Columbus | Ohio | 43221 | — |
| Teva Investigational Site 1244 | Portland | Oregon | 97225 | — |
| Teva Investigational Site 1258 | Philadelphia | Pennsylvania | 19107 | — |
| Teva Investigational Site 1281 | Nashville | Tennessee | 37205 | — |
| Teva Investigational Site 1284 | San Antonio | Texas | 78231 | — |
| Teva Investigational Site 1248 | Richmond | Virginia | 23298-0599 | — |
| Teva Investigational Site 1270 | Roanoke | Virginia | 24018 | — |
| Teva Investigational Site 1253 | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 134 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00605215, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 20, 2022 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00605215 live on ClinicalTrials.gov.